You are here

Phase 2 Clinical Trial of Vascular Endothelial Growth Factor-2 in Severe Cardiovascular Disease Commences

ATLANTA--(BUSINESS WIRE)--July 15, 2004--Corautus Genetics Inc. (AMEX: CAQ) announces that the U.S. Food and Drug Administration (FDA) has approved the commencement of its Phase IIB clinical trial for the treatment of severe cardiovascular disease.

The trial, as previously announced, will be a national, randomized, double-blinded, dose ranging and placebo controlled study of up to 404 patients in up to 20 centers in the United States evaluating the efficacy and safety of defined doses of Vascular Endothelial Growth Factor-2 (VEGF-2) to be percutaneously delivered via Boston Scientific Corporation's (NYSE: BSX) Stiletto(TM) endocardial direct injection catheter. The trial will enroll qualified patients with Class III or IV angina. Patient enrollment is expected to commence during the third quarter.

Richard E. Otto, President and CEO, of Corautus stated, "Obtaining FDA approval to commence our Phase IIB clinical trial is an important milestone for Corautus. We have worked diligently with Boston Scientific to design a study to assess the effectiveness and safety of our therapeutic and the delivery system to promote angiogenesis in the heart and we are pleased that we can proceed to finalize documentation and begin the patient enrollment process."

Source: Corautus Genetics Inc.

Recent Headlines

First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses